Use of recombinant human activated protein C in nonmenstrual staphylococcal toxic shock syndrome.
Toxic shock syndrome (TSS) is a serious, potentially life-threatening condition resulting from an overwhelming immunological response to an exotoxin released by Staphylococcus aureus and group A streptococci. High index of suspicion, early diagnosis and aggressive therapeutic measures must be instituted in view of high mortality of the TSS. In recent years, new agents have been tested to reduce morbidity and mortality in patients with severe sepsis, in addition to standard supportive measures. Among them, recombinant human activated protein C (rhAPC) has been reported to significantly reduce mortality and morbidity in patients with severe sepsis and two or more acute organ failures. We describe our experience with this drug in the early reversal of septic shock from TSS.
Department of Medical ICU, Indraprastha Apollo Hospital, New Delhi, India.
Prashant
P
Nasa
Deepak
D
Sehrawat
Sudha
S
Kansal
Rajesh
R
Chawla
N Engl J Med. 2001 Mar 8;344(10):699-709
11236773
Crit Care. 2007;11 Suppl 5:S3
18269690
Clin Microbiol Rev. 1988 Oct;1(4):432-46
3069202
Ann Fr Anesth Reanim. 2009 Jan;28(1):91-5
19108981
Crit Care Med. 2004 Nov;32(11 Suppl):S595-7
15542969
MMWR Morb Mortal Wkly Rep. 1997 Jun 6;46(22):492-3; discussion 494-5
9194399
Crit Care Med. 2005 Jul;33(7):1538-48
16003060
Crit Care Med. 2008 Jan;36(1):296-327
18158437
South Med J. 2006 Nov;99(11):1295-6
17195430
Scand J Infect Dis. 2006;38(11-12):960-3
17148061
Int J Antimicrob Agents. 2001 Oct;18(4):395-8
11691576
J Infect Dis. 1985 Mar;151(3):514-22
3871826
Crit Care Resusc. 2003 Sep;5(3):189-92
16573482